Navigation Links
Preliminary Results of a Large Scale Study Show ConvaTec Moldable Technology™ Skin Barriers Help to Prevent and Improve Peristomal Skin Issues in Ostomy Patients
Date:6/23/2011

s in the first arm who completed the study (N=305), most of whom had normal skin at baseline, skin integrity was maintained or improved in nearly all patients (95 percent).  Among patients in the second arm who completed the study (N=140), all of whom had skin issues at baseline, nearly all patients (90 percent) were classified as having normal skin or improved pre-existing lesions by the end of the study period.

Participants who completed the final product evaluation of the study also reported very high levels of satisfaction with ConvaTec Moldable Technology™ Skin Barriers, with both groups combined providing ratings of "excellent" or "good" in excess of 80 percent across all criteria including comfort, ease of molding, ease of application and removal, level of confidence and overall evaluation.

ConvaTec Moldable Technology™ Skin Barriers with Rebounding Memory Technology™ are the only skin barriers with a patented** tri-laminate construction that actively adjusts to the shape and contours of the stoma. ConvaTec Moldable Technology™ Skin Barriers are supported by extensive clinical experience demonstrating their ability to prevent leaks and protect the peristomal skin.(1) (2)

About Peristomal Skin Disorders

Peristomal skin disorders and lesions are common complications affecting people living with an ostomy.(3) While estimates of the incidence of peristomal skin disorders vary, a Danish study showed that these complications can appear in 45 percent of patients living with a stoma.(3)  Research also indicates that peristomal skin disorders negatively impact quality of life, including the psychological and social behavior of patients.(4)(5)

About the SACS™ Instrument

The SACS™ Instrument was developed to help establish a standard universal scale for assessing and classifying peristomal lesions by type of lesion (L) and the topographical location of skin breakdown
'/>"/>

SOURCE ConvaTec
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, received official notification from the European Patent Office ... patent supporting its iSONEP™ and ASONEP™ programs. ... No. 2087002, claims compositions of matter related to ... compounds, iSONEP and ASONEP. Sonepcizumab is an antibody ...
(Date:10/20/2014)... NEW YORK and RALEIGH, N.C., Oct. 20, ... the Hereditary Neuropathy Foundation (HNF), both philanthropies, announced ... develop drug candidates for the treatment of the ... BioPontis Alliance announced its alliance model ... is a first demonstration of a collaborative model ...
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... WASHINGTON, June 8, 2011 /PRNewswire/ -- A ... (AUA) Annual Meeting shows the less-invasive Pro-Vas® occlusion as ... The clinical study results were presented by Douglas ... AUA Annual Meeting. The AUA meeting is the world,s ...
... 2011 On June 7, 2011, Vycor Medical, Inc. ... in Units comprising Preferred Shares and Warrants (the "Units") ... pursuant to the terms of separate Series C Convertible ... of the Investors. This sale is an initial closing ...
Cached Medicine Technology:Phase I Pro-Vas® Effectiveness Study Presented at AUA Meeting 2Vycor Medical, Inc. Completes Equity Capital Raise 2Vycor Medical, Inc. Completes Equity Capital Raise 3
(Date:10/20/2014)... October 20, 2014 Women’s health specialist, ... Obstetrics & Gynecology of Columbus, Inc., A Division of ... services to more than 100,000 patients annually. Dr. Murphy ... ages and stages of a women’s life. She is ... in Westerville and Dublin. , Dr. Murphy offers ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Zereana Jess-Huff, a ... Mrs. Maryland 2014 on a platform to think outside the ... and uses her position to raise awareness about women’s other ... for breast cancer. You say the color pink and everybody ... know for a fact that it has not been won ...
(Date:10/20/2014)... October 20, 2014 Principle Business Enterprises, ... pride in manufacturing top-of-the-line absorbent products. The company ... its most popular brand, Tranquility® Premium Protection absorbent products. ... new website, gave its packaging a new look, and ... brand message to the public. , The new website, ...
(Date:10/20/2014)... 2014 Rockynol Retirement Community ... Oct. 14. The $11 million project will include the ... cooked-to-order kitchen with full-service restaurant style dining. , “We ... first class Assisted Living apartments,” said Kara Hanzie, Rockynol ... highest quality of care and this investment is proof ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, 2014 and ... AAP, http://www.ohioaap.org ) is joining the National Highway Traffic ... talk to their teens and always set the rules before ... leading cause of death for U.S. teens. In 2012, there ... (42%) of those teen drivers were killed in crashes. While ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... wellbeing in rich countries might depend more on reductions in ... study published today on bmj.com . , Poorer ... But a recent UNICEF report detailing 40 indicators of ... fared worse than in any of the other rich countries. ...
... (NYSE: WPI ), a leading specialty pharmaceutical,company, ... 48, as Senior,Vice President and Chief Financial Officer. ... 20 years of executive,pharmaceutical experience in finance, operations, ... Chief Financial Officer for Watson,Mr. Durand will be ...
... of families with deployed Service members ... ... to the Oregon National Guard,s Emergency Relief fund, which,will support the needs of ... "TriWest made the contribution with the hope that we can make a,difference in ...
... Use of ABILIFY in Patients Ages 10 to 17 ... ... PRINCETON, N.J., Nov. 15 ,Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company ... for filing and granted a Priority Review to the supplemental New,Drug Application ...
... alternative for patients with erosive gastroesophageal reflux disease ... (GERD) who cannot swallow ... of Wyeth (NYSE: WYE ), announced today that the,U.S. ... Delayed-Release Oral Suspension, a new addition,to the Protonix family of ...
... Memphis PGA Tour Stop ... Jude, MEMPHIS, Tenn., Nov. 15 Stanford Financial Group CFO,James ... joined Tony,Thomas from St. Jude and Laurie Tucker, Senior Vice President ... from the,inaugural Stanford St. Jude Championship. The donation from the 2007 ...
Cached Medicine News:Health News:Low standards of child well-being linked to greater income inequality 2Health News:Watson Names Mark Durand Chief Financial Officer 2Health News:TriWest Contributes $30,000 to Oregon National Guard Fund 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 3Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 4Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 5Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 6Health News:Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension 2Health News:Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension 3Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 2Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 3Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: